References
- Elbashir SM, Lendeckel W, Tuschl T, Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;15(2):188–200. doi: 10.1101/gad.862301
- Fire A, Xu S, Montgomery MK. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. doi: 10.1038/35888
- Bilir Ö, Telli O, Norman C. Bilir, Ö, Telli, O, Norman, C, Budak, H, Hong, Y, Tör, M. Small RNA inhibits infection by downy mildew pathogen hyaloperonospora arabidopsidis. Mol Plant Pathol. 2019;20(11):1523–1534. doi: 10.1111/mpp.12863
- Kuscu C, Kumar P, Kiran M, et al. tRNA fragments (tRFs) guide Ago to regulate gene expression post-transcriptionally in a Dicer-independent manner. RNA. 2018;24(8):1093–1105. doi: 10.1261/rna.066126.118
- Fukaya T, Tomari Y. MicroRNAs mediate gene silencing via multiple different pathways in drosophila. Mol Cell. 2012;48(6):825–836. doi: 10.1016/j.molcel.2012.09.024
- Ibrahim F, Rymarquis LA, Kim EJ, et al. Uridylation of mature miRnas and siRnas by the MUT68 nucleotidyltransferase promotes their degradation in chlamydomonas. Proc Natl Acad Sci U S A. 2010;107(8):3906–3911. doi: 10.1073/pnas.0912632107
- Brody H, Maiyuran S. Rnai-mediated gene silencing of highly expressed genes in the industrial fungi Trichoderma reesei and aspergillus niger. Ind Biotechnol. 2009;5(1):53–60. doi: 10.1089/ind.2009.5.53
- Elbashir SM, Harborth J, Lendeckel W, Harborth, J, Yalcin A, Weber K, Elbashir SM, Lendeckel W, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494–498. doi: 10.1038/35078107
- Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science. 1999;286(5441):950–952. doi: 10.1126/science.286.5441.950
- Collingwood MA, Rose SD, Huang L, et al. Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides. 2008;18(2):187–200. doi: 10.1089/oli.2008.0123
- Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol. 2005;23(2):222–226. doi: 10.1038/nbt1051
- D’Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting — strategies and applications. J Control Release. 2015;203:126–139. doi: 10.1016/j.jconrel.2015.02.022
- Pricer WE, Hudgin RL, Ashwell G, et al. [87] A membrane receptor protein for asialoglycoproteins. In: Kaplan N, Colowick N, Jakoby W, and Wilchek M, editors Affin. Tech. - Enzym. Purif. Part B. Vol. 34. Elsevier; 1974. p. 688–691.
- Manoharan M Chirally-enriched double-stranded RNA agents. US11597932B2, 2023.
- Brown BD. Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA. US10487330B2. 2019.
- Schlegel MK Serpina1 iRNA compositions and methods of use thereof. US10995336B2, 2021.
- Foster D Angiotensinogen (AGT) iRNA compositions and methods of use thereof, 2021.
- Bondurant LD Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof. US11613751B2, 2023.
- Fitzgerald K Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof. US11034958B2, 2021.
- Fitzgerald K Complement component C5 iRNA compositions and methods of use thereof. US9249415B2, 2016.
- Beigelman L RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA). US9657294B2, 2017
- Zewge D Post-synthetic chemical modification of RNA at the 2′-position of the ribose ring via “click” chemistryp. US9441228B2, 2016.
- Maier M Modified double-stranded RNA agents. US11427822B2, 2022.
- Chang W Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT). US10738308B2, 2020
- Payne JE MultiLigand agent for drug delivery. US9962449B2, 2018.
- Manoharan M Carbohydrate conjugates as delivery agents for oligonucleotides. US9370581B2. 2016.
- Rajeev KG Compositions and methods for targeted RNA delivery. US11207416B2, 2021.
- Lewis DL Compositions for targeted delivery of siRNAp. US9345775B2, 2016.
- Zhang H-L. Current status and patent prospective of lipid nanoparticle for mRNA delivery. Expert Opin Ther Pat. 2023;33(2):125–131. doi: 10.1080/13543776.2023.2195541
- Choung S, Kim YJ, Kim S, et al. Chemical modification of siRnas to improve serum stability without loss of efficacy. Biochem Biophys Res Commun. 2006;342(3):919–927. doi: 10.1016/j.bbrc.2006.02.049
- Prakash TP. An overview of sugar-modified oligonucleotides for antisense therapeutics. Chem Biodivers. 2011;8(9):1616–1641. doi: 10.1002/cbdv.201100081
- Zhang HL, Li Y. Antibacterial and Antimalarial Therapeutic Agents: A Patent Perspective. Recent Adv Inflamm Allergy Drug Discov. 2023 Oct 25. doi: 10.2174/0127722708268538231010041307. Epub ahead of print. PMID: 37885108.
- Zhang H-L, Li Y. The Patent Landscape of BRAF Target and KRAS Target. Recent Pat Anticancer Drug Discov. 2023 18;18(4):495–505. doi: 10.2174/1574892818666221207091329
- The U.S. Food and Drug Administration. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-targeted-rna-based-therapy-treat-rare-disease.
- The Food and drug Administration. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-givosiran-acute-hepatic-porphyria.
- The U.S. Food and Drug Administration. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder.
- The U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215515s002lbl.pd
- Janas MM, Schlegel MK, Harbison CE, et al. Selection of GalNAc-conjugated siRnas with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9(1):9.723. doi: 10.1038/s41467-018-02989-4
- https://www.hemophiliafed.org/sanofi-two-published-studies-highlight-fitusirans-potential/#:~:text=Across%20both%20clinical%20studies%2C%20prophylactic%20treatment%20with%20fitusiran,treatments%3B%20and%20showed%20improvement%20in%20quality%20of%20life.
- Baum MA, Langman C, Cochat P, et al. PHYOX2 study investigators. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 2023;103(1):207–217. doi: 10.1016/j.kint.2022.07.025